Formulation Innovation and Technological Capability in Pulmonary Drug Delivery: A Literature-based Conceptual Framework for Delivery Performance and Commercialisation Implementation

Main Article Content

Zhu Xinyu, Sreemoy Kanti Das

Abstract

Developing a successful pulmonary drug delivery product requires addressing multiple aspects, including, but not limited to, the formulation, the device, how the patient will use the product, manufacturing, and regulations. This research takes a user-centered approach to developing a conceptual framework to illustrate the intersection of innovation in pulmonary drug delivery formulations (NFI) and the “organization’s capability in pulmonary drug delivery (ATC). The framework draws upon all pertinent literature and reflects regulatory supports (RS) as a buffer between the pulmonary drug delivery performance (PDDP) and Commercial Implementation (CIS). This research is a theory-focused, literature-synthesizing effort. No primary or secondary data, experiments, clinical or product sales data are analyzed. This research incorporates innovation and dynamic-capabilities theory, as well as pharmaceutical quality and methodology literature on construct specification, mediation, and moderation. The main conclusion drawn from the research is that delivery improvement does not necessarily require delivery system innovation. It also may require consideration of device, process, and other factors. Regulatory supports, RS, are positioned as a moderator of PDDP and CIS. PDDP is position as a proximal construct of the CIS, and CIS is concerned with the organizational unit’s readiness and progress toward commercializing the product rather than profits or sales. The framework includes 8 relationships. These 8 relationships and 1 moderator, RS, are bound by theory. This paper proposes construct boundaries and provides a mechanism-based approach to identify barriers, along with a clarification of terms and a means to validate those barriers. Barriers may be identified via item clarity and instrumented by a set of delivery indicators. Barriers may be scoped to the product and jurisdiction. Barriers may be sequenced over time. Barriers may be isolated to the implementation and/or commercialization of a product.

Article Details

Section
Articles